Plasma microRNAs are considered to be potential diagnostic biomarkers for endometriosis. 12
inhibition of their translation, or binding to RNA silent complexes composed of multiple proteins. 1 Target gene expression can be suppressed by completely binding to the non-coding region of the 2 target gene 3'[5Teague EM2010, 6Caporali A2011]. It is important that miRNA can target multiple 3 mRNA expressions, and one mRNA can be regulated by multiple miRNAs at the same time 4 through this complex post-transcription regulatory network [7Bartel DP2004, 8Lagos-Quintana 5 M2001]. miRNA is involved in almost all pathophysiological processes in the body. To date, more 6 than 1,881 miRNA precursors, encoding more than 2500 miRNAs, have described as mature 7 miRNA in humans. With the increased understanding of the mechanism of action of miRNAs and 8 the study of the biogenesis, function, role, and characterization of miRNA, candidate biomarkers 9 for many diseases have emerged, such as cancer, coronary artery disease, and gynecological 10 diseases, including endometriosis [9-13Mitchell2008,Small2011,Lawrie2008,Alessandra2010, 11 Vodolazkaia2012]. Therefore, miRNAs have substantial potential as promising markers for 12 diagnosis, prognosis and personalized targeting. 13
Endometriosis (EMS) refers to a common estrogen-dependent chronic disease in the endometrium 14 (glands and interstitial substances) that occurs in other parts of the uterus and affects nearly 10 % 15 of women of childbearing age [14-16Giudice2004,Tamaresis2014,Giudice2010]. This disease 16 primarily causes pelvic pain and infertility. The prevalence of this disorder is an estimated global 17 average of 176 million individuals, in whom the diagnosis is delayed by 7 years, and the mean 18 diagnostic age is 32.5-36.4 years, depending on the research population [17Tokushige2011] . 19
Although significant progress has been made in the study of the etiology and pathogenesis of EMS, 20
unfortunately, compared to other chronic diseases, it is difficult to diagnose, and the diagnosis of 21 EMS is often delayed because there are currently no accurate, accessible and non-invasive 22 diagnostic tools. Early diagnosis and treatment of EMS remain difficult. Therefore, it is urgent to 23 further explore the etiology and pathogenesis of EMS to identify specific and sensitive detection 24 indicators and treatment targets and provide new ideas and strategies for early clinical diagnosis 25 and treatment [18Burney2012] . In several studies, a specific miRNA has been identified as a 26 potential biomarker of the disease. These and other miRNAs have been associated with target 27 genes and functional pathways in the disease-specific pathophysiology. The occurrence of 28 endometriosis involves various factors, such as hormones, inflammatory factors, and hypoxic 29 microenvironments. In recent years, studies have shown that tiny RNA also plays an important 30 role in the development of endometriosis. There are differences in the expression of miRNA 31 between ectopic endometrial tissue cells and normal tissue cells. These differences in the 32 expression of miRNA may be related to the occurrence and development of EMS. The expression 33 pattern of miRNA in the endometrium in endometriosis is based on patients and control women as 34 well as different individuals who have endometriosis. miRNA may be an attractive candidate for 35 new diagnostic markers and treatment interventions for endometriosis. These small non-coding 36 molecules have become attractive candidates as new biomarkers for early non-invasive diagnosis 37
[19-22Jia2013,Fessbender2010,Cho2015,Cosar2016]. Study of this disease may lead to valuable 38 benefits for patients by reducing the recurrence rates in terms of prognosis and improvements. 39
In this study, a systematic review was conducted of the key serum miRNAs predicted for 40 endometriosis diagnosis. GEO (Gene expression omnibus) is a gene expression database created 41 and maintained by the NCBI (National Biotechnology Information Center of the United States). 42
The purpose of this study is to identify miRNA data downloaded from the GEO database to 43 determine serum differences between normal women and patients with endometriosis. In miRNAhigh-throughput analysis, miRNA target genes are shown to be differentially expressed and their 1 function is annotated, and a miRNA feature that can effectively diagnose endometriosis is 2 constructed. In addition, the TFactS database was analyzed using analytical transcription factors. 3
This study shows the importance of miRNA in the diagnosis of endometriosis. 4
Methods and materials 5

Systematic review 6
A systematic review was conducted of all the pertinent studies that were identified in the 7 electronic PubMed, ScienceDirect, and the Cochrane Central Register of Controlled Trials 8 (CENTRAL) databases that examined plasma microRNAs as potential diagnostic biomarkers for 9 endometriosis from 1966 to January 2019. The search strategy included the terms miRNA, 10 microRNA, circular, blood, serum, and plasma. The search was concluded by (1) perusal of the 11 reference sections of all relevant studies in English and (2) a manual search of the key journals and 12 abstracts from the major annual meetings in the fields of endocrinology and obstetrics and 13 gynecology. Articles were excluded from the analysis that lacked adequate disease-matched 14 control groups. The control groups consisted of women without endometriosis. 15
Screening of the endometriosis miRNA expression dataset 16
The Series Matrix file of GSE46735 was downloaded from the GEO 17 functional annotation tools to identify biological mechanisms associated with a number of genes 2 or proteins. GO (Gene Ontogirl) and KEGG (Kyoto Engineering of Genes and Genomes) pathway 3 events were analyzed for particular genes. A P-value < 0.05 was set as the cut-off for significance. 4
Analysis of the regulation of miRNA targeting in endometriosis serum was used to determine up-5 and downregulation of miRNA (Essaghir et al.) using the TFactS database (2010) 6 (Http://www.tfacts.org/). Only four indicators (P value, Q value, E value, and FDR) were used in 7 advance to indicate that a value which was less than 0.05 was considered to be a reliable 8 transcription factor scope. State on translation factors (TF) of target DEMs of up and 9 down-protected miRNA regulated objects where we have to go to the special study. 10
Results 11
Systematic review 12
The electronic search strategy identified 160 potentially relevant articles (PubMed, 136; 13 ScienceDirect, 24; and Cochran Library, 0), which filtered articles by the title, summary, full text, 14 or a combination of these factors. Of these 160 articles, 84 articles were excluded because of not 15 meeting the inclusion criteria after reading the abstracts. The full studies of the remaining 76 16 studies, which focused on miRNAs used in the diagnosis of endometriosis, were then carefully 17
read. An additional 65 articles were excluded because the sample originated from peritoneal fluid 18 or urine. In particular, we excluded trials as follows: data on the diagnosis of endometriosis via a 19 blood test identifying microRNAs were not available from the papers and could not be obtained 
21-31 25
Jia2013,Cho2015,Cosar2016,Suryawanshi2013,Wang2013,Wang2016,Nothnick2016,Maged2018, 26
Wang2018,Rekker2015,Pateisky2018,Shakiba2008]. A total of 472 endometriosis serum samples 27 and 357 normal corresponding serum samples were collected (some articles studied serum and 28 some studies studied plasma; for simplicity, we used serum instead of serum/plasma). The 29 subjects' age in the studies ranged from 26 to 53 years old. Table 1 Has-miR-155-5p, hsa-miR-128-3p, hsa-miR-1-3p, and hsa-miR-532-5p of the upregulated 19 differentially expressed miRNAs (LogFC>1, P<0.05) and hsa-miR-574-3p, hsa-miR-23a-3p, 20 hsa-miR-520d-5p, hsa-miR-433-3p, hsa-miR-485-5p, and hsa-miR-122-5p of the downregulated 21 differentially expressed miRNAs (LogFC<-1, P<0.05) were significantly different. With respect to 22 patients who provided blood samples in the early proliferative, late proliferative and mid luteal 23 phases of the menstrual cycle (n = 47 total plasma samples), the cycle phase was verified 24 according to the hormonal profile. RNA was extracted from each sample, and the expression of 25 microRNAs was assessed using TaqMan Low Density Human miRNA arrays. Has-miR-155, 26 hsa-miR-218, hsa-miR-301b, hsa-miR-128, hsa-miR-532-5p, hsa-miR-22, hsa-miR-1, 27 hsa-miR-339-5p, and hsa-miR-143 in early proliferation; has-miR-155, hsa-miR-218, 28 hsa-miR-532-5p, hsa-miR-22, hsa-miR-1, hsa-miR-339-5p, hsa-miR-331-5p and hsa-miR-362-3p 29 in late proliferation; and has-miR-155, hsa-miR-218, hsa-miR-301b, hsa-miR-128, hsa-miR-133a, 30
and hsa-miR-143 in the mid luteal phase were upregulated and differentially expressed (LogFC>1, 31 P<0.05). Has-miR-574-3p, hsa-miR-23a, hsa-miR-500, hsa-miR-98, hsa-miR-7f, hsa-miR-451, 32 hsa-miR-122, hsa-miR-520d-5p, hsa-miR-15a and hsa-miR-409-5p in early proliferation, 33 hsa-miR-574-3p, hsa-miR-23a-3p, hsa-miR-98, hsa-miR-122, hsa-miR-874, hsa-miR-381, 34 hsa-miR-520d-5p, hsa-miR-452, hsa-miR-369-3p, hsa-miR-224, hsa-miR-502-5p, hsa-miR-320, 35 hsa-miR-433 and hsa-miR-23b in late proliferation and has-miR-574-3p, hsa-miR-382, 36 hsa-miR-23a, hsa-miR-10b, hsa-miR-485-5p, hsa-miR-520d-5p, hsa-miR-433, hsa-miR-452, 37 hsa-miR-130b and hsa-miR-874 in the mid luteal phase were downregulated and differentially 38 expressed (LogFC<-1,P<0.05) and were significantly different. The consistently upregulated and 39 downregulated genes in independent cohorts in all three phases were identified using Venn 40 analysis, and a Venn diagram was generated by FunRich (Fig3) . As a result, we identified 41 has-miR-155-5p as having unregulated expression and hsa-miR-574-3p, hsa-miR-23a-3p, and
The target genes of four miRNAs were predicted using the TargetScan, miRDB, RNA22, 1 miRWalk and miRanda online analysis tools. Thirty-nine overlapping genes of miR-155-5p, 4 2 overlapping genes of miR-574-3p, 70 overlapping genes of miR-23a-3p, and 107 overlapping 3 genes of miR-520d-5p were identified. Enrichment analysis of the target genes was subsequently 4 performed to elucidate the biological function of the consensus target genes. TFs, 12 TFs were shared between the two target genes, accounting for 19.67 % of the total TFs. In 27 addition, the TFs corresponding to the regulation of miRNA target genes showed high specificity, 28 consistent with the results of the GO analysis, and enriched the regulation of miRNA target genes 29 during the regulation of transcription. According to the results of the analysis, the main TFs with 30 credibility E values and cross ratios were not more than 0.05, and only the TFs CTNNB1, MYC, 31
and ES R1 had a hard cross rate. 32
Discussion 33
Endometriosis is the main cause of pelvic pain and low fertility. However, it is difficult for the 34 diagnosis of endometriosis, and there is no clear diagnostic biomarker. Laparoscopy is currently 35 the gold standard for the endometriosis diagnosis; however, it is traumatic. Many clinicians 36 evaluate a series of clinical symptoms of endometriosis prior to seeking a definitive diagnosis by 37 laparoscopy. Moreover, experimental treatment drugs have significant side effects and are 38 typically not completely eradicated [31, 32Shakiba2008,Johnson2013] . At the same time, 70-75% 39 of visually diagnosed lesions are confirmed histologically in laparoscopy, thus hindering their 40 widespread use [33Nnoaham2011]. In addition, CA125 is only 21-50% sensitive for the diagnosis 41 of endometriosis. Therefore, there is a need to develop a non-invasive diagnostic test for 42 endometriosis. In recent years, studies on miRNAs have shown that their expression levels areexpected to be non-invasive diagnostic markers for EMS. 1 miRNA achieves the regulation of EMS through its regulation[34Pan2008]. Using TaqMan 2 microRNA chips to detect changes in serum miRNA expression levels in EMS patients and 3 healthy control groups, studies showed that miR-199 and miR-122 were increased in the serum of 4 EMS patients compared to healthy control groups[24Wang2013]. miR-141, miR-9, MiR-145, and 5 miR-542-3p were downregulated, and miR-199 and miR-122 could be used to distinguish between 6 severe and mild EMS patients. In addition, the area under the ROC curve measured jointly by 7 miR-199, miR-122, miR-145 and miR-542-3p was 0.994, and the sensitivity and specificity were 8 93.22% and 96.00%, respectively. It was proven that the combined detection of miR-199, 9 miR-122, miR-145 * and miR-542-3p as non-invasive biomarkers of EMS had significant 10 diagnostic significance. At the same time, it was found that 27 miRNAs were differentially 11 expressed in the serum of EMS patients compared to the healthy control group using TaqMan 12 microRNA chips [19Jia2013] . After testing with Real-time PCR, it was found that miR-17-5p, 13 miR-20a and miR-22 showed significant downward expression, indicating that these miRNAs can 14 be used as serum markers to diagnose endometriosis. EMS is characterized by the growth of the 15 endometrium outside the endometrium. This process is closely related to factors such as vascular 16 endothelial growth factor-A, which regulates angiogenesis, and thrombin-sensitive protein, 17 miR-222, and miR-17-5p, which regulate the expression of angiogenic factors and play important 18 roles in the pathogenesis of EMS. MiR-199a can inhibit the invasion of endometrial stromal cells 19 by inhibiting the IKKβ/NF-κB signaling pathway and decreasing IL-8 expression, and it can be 20 used as a serum marker for metastasis in EMS patients [36, 37Dai2012,Ramon2011]. Therefore, 21 circulating miRNA can be used as a biomarker for the early diagnosis of small and mild 22
endometriosis. 23
Because of the differential expression of miRNAs in the review, we downloaded a dataset from 24 the GEO database to validate the exact plasma miRNA levels. Unexpectedly, we found that 25 miR-155, miR-128, miR-1 and miR-532 of the upregulated miRNAs and miR-574, miR-23a, 26 miR-520d, miR-433, miR-485 and miR-122 of the downregulated miRNAs were differentially 27 significantly expressed and associated with the diagnosis of endometriosis patients in the present 28 study. With respect to the phases of the menstrual cycle, we found that miR-155, which 29 upregulated miRNA expression, and miR-574, miR-23a, and miR-520d, which downregulated 30 miRNAs expression, could be used as a multi-marker based model to provide more powerful 31 information for the prediction of EMS in patients. When it is performed enrichment analysis of the 32 four-miRNAs for the prediction and function analyses of biological processes, cellular 33 components, KEGG pathways, and molecular function. Furthermore, we also assessed the miRNA 34 target genes during the regulation of transcription. The results of the functional enrichment 35 analysis implied that the three target genes of miRNAs related to endometriosis might be involved 36 in various pathways, including neurotrophin, Hippo, oocyte meiosis, ubiquitin mediated 37 proteolysis, HTLV-Infection, FoxO, and Rap1 signaling pathways. Unsurprisingly, only the 38 transcription factors CTNNB1, MYC, and ES R1 agreed with this conclusion. 39
In short, in recent years, with the in-depth study of miRNAs, the different stages of disease 40 occurrence and development have been shown to be accompanied by changes in miRNA 41 expression, and a deep understanding of miRNAs helps to scientifically grasp the internal 42 mechanism of disease occurrence. In addition, miRNA expression levels are expected to beevaluation. In summary, a number of miRNAs have been found to be differentially expressed in 1 the plasma of women with endometriosis, and the mechanism of serum miRNA dysregulation 2 remains unknown. To date, as indicated by the different results from the review and microarray 3 datasets, circulating miR-155, miR-574, miR-23a, and miR-520d may be powerful biomarkers for 4 diagnosis of endometriosis, accurate chemotherapy and targeted therapy; however, additional 5 research is required to determine the repeatability and consistency of the results. These findings 6 provide new insights into the early diagnosis and detection of endometriosis. 7
Conclusions 8
Comprehensive analysis of the pooled data provides strong evidence that circulating unregulated 9 miR-155 expression and downregulated miR-574, miR-23a, and miR-520d expression are 10 significantly associated with the diagnosis of endometriosis. Abnormal expression of aberrant 11 miR-155 and low expressions of miR-574, miR-23a, and miR-520d may be promising diagnostic 12 biomarkers for non-invasive endometriosis testing. 13 14
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